155 related articles for article (PubMed ID: 28881820)
1. Brain metastases in patients with non-small cell lung cancer: the role of mutated-
Hsiao SH; Chou YT; Lin SE; Hsu RC; Chung CL; Kao YR; Liu HE; Wu CW
Oncotarget; 2017 Aug; 8(32):53405-53418. PubMed ID: 28881820
[TBL] [Abstract][Full Text] [Related]
2. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
Won YW; Han JY; Lee GK; Park SY; Lim KY; Yoon KA; Yun T; Kim HT; Lee JS
J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039
[TBL] [Abstract][Full Text] [Related]
3. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
[TBL] [Abstract][Full Text] [Related]
4. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis.
Sheng M; Wang F; Zhao Y; Li S; Wang X; Shou T; Luo Y; Tang W
Eur J Clin Pharmacol; 2016 Jan; 72(1):1-11. PubMed ID: 26490356
[TBL] [Abstract][Full Text] [Related]
5. Patterns of spread and prognostic implications of lung cancer metastasis in an era of driver mutations.
Hsu F; De Caluwe A; Anderson D; Nichol A; Toriumi T; Ho C
Curr Oncol; 2017 Aug; 24(4):228-233. PubMed ID: 28874890
[TBL] [Abstract][Full Text] [Related]
6. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
Karachaliou N; Mayo-de las Casas C; Queralt C; de Aguirre I; Melloni B; Cardenal F; Garcia-Gomez R; Massuti B; Sánchez JM; Porta R; Ponce-Aix S; Moran T; Carcereny E; Felip E; Bover I; Insa A; Reguart N; Isla D; Vergnenegre A; de Marinis F; Gervais R; Corre R; Paz-Ares L; Morales-Espinosa D; Viteri S; Drozdowskyj A; Jordana-Ariza N; Ramirez-Serrano JL; Molina-Vila MA; Rosell R;
JAMA Oncol; 2015 May; 1(2):149-57. PubMed ID: 26181014
[TBL] [Abstract][Full Text] [Related]
7. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
[TBL] [Abstract][Full Text] [Related]
8. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Jackman DM; Yeap BY; Sequist LV; Lindeman N; Holmes AJ; Joshi VA; Bell DW; Huberman MS; Halmos B; Rabin MS; Haber DA; Lynch TJ; Meyerson M; Johnson BE; Jänne PA
Clin Cancer Res; 2006 Jul; 12(13):3908-14. PubMed ID: 16818686
[TBL] [Abstract][Full Text] [Related]
9. Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival.
Okuda Y; Sato K; Sudo K; Hasegawa Y; Asano M; Miura H; Takeda M; Sano M; Watanabe H; Kobayashi H; Niioka T; Miura M; Ito H
Cancer Chemother Pharmacol; 2017 May; 79(5):1013-1020. PubMed ID: 28391354
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea.
Baek JH; Sun JM; Min YJ; Cho EK; Cho BC; Kim JH; Ahn MJ; Park K
Lung Cancer; 2015 Feb; 87(2):148-54. PubMed ID: 25498243
[TBL] [Abstract][Full Text] [Related]
11. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.
Yang CH; Yu CJ; Shih JY; Chang YC; Hu FC; Tsai MC; Chen KY; Lin ZZ; Huang CJ; Shun CT; Huang CL; Bean J; Cheng AL; Pao W; Yang PC
J Clin Oncol; 2008 Jun; 26(16):2745-53. PubMed ID: 18509184
[TBL] [Abstract][Full Text] [Related]
12. Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring EGFR Exon 19 Deletion and Exon 21 L858R Substitution.
Koyama N; Watanabe Y; Iwai Y; Kawamura R; Miwa C; Nagai Y; Hagiwara K; Koyama S
Chemotherapy; 2017; 62(3):151-158. PubMed ID: 28110331
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy of gefitinib in patients with non-small cell lung cancer according to the type of epidermal growth factor receptor mutation.
Igawa S; Kasajima M; Ishihara M; Kimura M; Hiyoshi Y; Asakuma M; Otani S; Katono K; Sasaki J; Masuda N
Oncology; 2014; 87(4):215-23. PubMed ID: 25034225
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 L858R mutation in non-small-cell lung cancer: Systematic review and meta analysis.
Liu Y; Ren Z; Wang J; Zhang S
Thorac Cancer; 2016 Jul; 7(4):406-14. PubMed ID: 27385982
[TBL] [Abstract][Full Text] [Related]
15. Identification of subgroup patients with stage IIIB/IV non-small cell lung cancer at higher risk for brain metastases.
Hsiao SH; Chung CL; Chou YT; Lee HL; Lin SE; Liu HE
Lung Cancer; 2013 Nov; 82(2):319-23. PubMed ID: 24018025
[TBL] [Abstract][Full Text] [Related]
16. EGFR and erbB2 mutation status in Japanese lung cancer patients.
Sasaki H; Shimizu S; Endo K; Takada M; Kawahara M; Tanaka H; Matsumura A; Iuchi K; Haneda H; Suzuki E; Kobayashi Y; Yano M; Fujii Y
Int J Cancer; 2006 Jan; 118(1):180-4. PubMed ID: 16003726
[TBL] [Abstract][Full Text] [Related]
17. L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer.
Sasaki H; Endo K; Takada M; Kawahara M; Kitahara N; Tanaka H; Okumura M; Matsumura A; Iuchi K; Kawaguchi T; Yukiue H; Kobayashi Y; Yano M; Fujii Y
Lung Cancer; 2006 Oct; 54(1):103-8. PubMed ID: 16890322
[TBL] [Abstract][Full Text] [Related]
18. The impact of epidermal growth factor receptor mutations on the prognosis of resected non-small cell lung cancer: a meta-analysis of literatures.
He Q; Xin P; Zhang M; Jiang S; Zhang J; Zhong S; Liu Y; Guo M; Chen X; Xia X; Pan Z; Guo C; Cai X; Liang W; He J
Transl Lung Cancer Res; 2019 Apr; 8(2):124-134. PubMed ID: 31106123
[TBL] [Abstract][Full Text] [Related]
19. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis.
Kawahara A; Yamamoto C; Nakashima K; Azuma K; Hattori S; Kashihara M; Aizawa H; Basaki Y; Kuwano M; Kage M; Mitsudomi T; Ono M
Clin Cancer Res; 2010 Jun; 16(12):3163-70. PubMed ID: 20423982
[TBL] [Abstract][Full Text] [Related]
20. Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features.
Sekine A; Kato T; Hagiwara E; Shinohara T; Komagata T; Iwasawa T; Satoh H; Tamura K; Kasamatsu T; Hayashihara K; Saito T; Takahashi H; Ogura T
Lung Cancer; 2012 Jul; 77(1):64-9. PubMed ID: 22335887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
